- Home
- XP vs LEGN Comparison
XP vs LEGN Comparison
Compare XP & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XP
- LEGN
- Stock Information
- Founded
- XP 2001
- LEGN 2014
- Country
- XP Cayman Islands
- LEGN United States
- Employees
- XP N/A
- LEGN N/A
- Industry
- XP Investment Bankers/Brokers/Service
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- XP Finance
- LEGN Health Care
- Exchange
- XP Nasdaq
- LEGN Nasdaq
- Market Cap
- XP 7.5B
- LEGN 7.0B
- IPO Year
- XP 2019
- LEGN 2020
- Fundamental
- Price
- XP $18.69
- LEGN $29.05
- Analyst Decision
- XP Buy
- LEGN Strong Buy
- Analyst Count
- XP 6
- LEGN 13
- Target Price
- XP $22.00
- LEGN $75.67
- AVG Volume (30 Days)
- XP 7.8M
- LEGN 1.6M
- Earning Date
- XP 05-20-2025
- LEGN 05-13-2025
- Dividend Yield
- XP 3.46%
- LEGN N/A
- EPS Growth
- XP 15.23
- LEGN N/A
- EPS
- XP 1.51
- LEGN N/A
- Revenue
- XP $2,886,046,386.00
- LEGN $728,303,000.00
- Revenue This Year
- XP $19.79
- LEGN $64.21
- Revenue Next Year
- XP $12.65
- LEGN $53.69
- P/E Ratio
- XP $12.33
- LEGN N/A
- Revenue Growth
- XP 9.27
- LEGN 112.46
- 52 Week Low
- XP $10.82
- LEGN $27.34
- 52 Week High
- XP $20.39
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- XP 73.66
- LEGN 40.43
- Support Level
- XP $18.30
- LEGN $28.14
- Resistance Level
- XP $19.85
- LEGN $31.12
- Average True Range (ATR)
- XP 0.58
- LEGN 1.87
- MACD
- XP 0.07
- LEGN -0.22
- Stochastic Oscillator
- XP 73.36
- LEGN 27.32
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.